PROPEL_white.png
PROPELPLUS_white.png
Screen Shot 2021-04-26 at 1.16.28 AM.png
IMG_5487.PNG

BMI has secured significant patents for CaVESWave ®, our signature Cardiovascular Emulation system, as well as patents for methods and apparatus, which has been deployed and refined through practice in the laboratories of many acclaimed institutions, such as Yale Neuroscience, Duke University Ex Vivo Organ Laboratory, Virginia Tech, Wake Forest School of Medicine, Porter Adventist, and UNC Kidney Center. 

BMI's organ perfusion system has proven its capabilities and versatility to support the ex vivo preservation of an array of organs and tissue.

Through ongoing deployments and partnerships BMI has been able to develop a reduced scale mobile platform, known as PROPEL ™, a name stemming from the acronym 'Pressure Regulated Organ Perfusion Extending Life', and conveying the significance of a device that BMI believes can carry donor organs further and for longer than has previously been possible. 

 

This ability to carry such precious cargo for longer--and thus over greater distances--opens-up coast-to-coast opportunity to find the best match for an organ and deliver it anywhere in the United States, indeed beyond.  

PROPEL  by BMI will be provided under a service delivery contract, known as PROPEL PLUS ™, together with BMI's proprietary perfusate and one-use organ cassette. 

BMI intends to seek FDA Clearance for its first mobile device in 2021 and once secured to begin by focusing on the Kidney Transplant market.